Johnson & Johnson stock (US4781601046): Leerink upgrades to Outperform, lifts target

Johnson & Johnson stock drew attention on May 13, 2026, as Leerink Partners upgraded its rating to Outperform from Market Perform while increasing the price target to $265 from $252, according to GuruFocus as of 05/13/2026. The firm cited robust momentum in the company's new drug development, particularly in immunology, oncology, and neurology, positioning it to outperform peers. Shares traded at $224.26 on NYSE, up 1.28% or $2.83, per the company's investor site as of 05/13/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Johnson & Johnson: core business model

Johnson & Johnson operates as a diversified healthcare company with two main segments: Innovative Medicine and MedTech. The Innovative Medicine unit focuses on pharmaceuticals across immunology, oncology, neuroscience, cardiovascular, and infectious diseases. MedTech provides surgical equipment, orthopaedics, and vision care products. This structure allows resilience through multiple revenue streams, with over 75% of sales from #1 or #2 global market positions, per the 2025 Investor fact sheet.

The company maintains a strong balance sheet, supporting 60+ consecutive years of dividend increases and returning over 65% of 5-year free cash flow to shareholders. For US investors, JNJ offers exposure to the world's largest healthcare market via its NYSE listing and dominant role in US pharmaceuticals.

Main revenue and product drivers for Johnson & Johnson

Key drivers include blockbuster drugs like Tremfya for immunology and new approvals such as Icotyde, anchoring growth post-Stelara biosimilar competition, as noted in recent updates from MarketBeat as of 05/13/2026. FY 2026 guidance stands at $11.45-$11.65 EPS. Q1 results showed $2.70 EPS, beating consensus of $2.68, with 32.60% return on equity.

MedTech growth stems from procedures and devices, bolstered by US market leadership. These factors underpin analyst optimism, including Leerink's upgrade highlighting pipeline strength for revenue acceleration.

Industry trends and competitive position

The healthcare sector faces biosimilar pressures but benefits from innovation in immunology and oncology. Johnson & Johnson differentiates via its broad portfolio and R&D scale, targeting double-digit revenue growth by decade's end, as previewed ahead of the December 8, 2026 analyst day.

Why Johnson & Johnson matters for US investors

As a NYSE-listed blue-chip with AAA credit rating—one of only two US firms—JNJ provides stability amid volatility. Its US headquarters and heavy domestic revenue exposure tie it to American economic health, making it a staple for diversified portfolios seeking healthcare defensiveness.

Conclusion

Johnson & Johnson continues to demonstrate resilience with recent analyst upgrades, solid Q1 results, and a promising pipeline offsetting biosimilar challenges. Trading at a premium P/E of 25.93 reflects market confidence in its growth trajectory. US investors value its stability and dividend history amid healthcare sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.